Men and women ages 18 years or older with a diagnosis of hidradenitis suppurativa (HS) and disease lasting for at least 6 months, may qualify to participate in this study. Individuals must have moderate to severe hidradenitis suppurativa with 5 or more inflammatory lesions in at least 2 distinct areas. Must also have no prior use of Cosentyx, Siliq or Taltz, and an inadequate response to oral antibiotics.
Eligible participants will receive investigational injection medication (active drug or placebo). Study medication and study-related care will be provided at no cost. Reimbursement for study-related expenses may be provided.
Study participation will last up to 71 weeks and include about 29 visits to the study centre.
Email Tina Craig, Clinical Research Coordinator at DermEffects to register.